PHAT 10-Q Quarterly Report Sept. 30, 2022 | Alphaminr
Phathom Pharmaceuticals, Inc.
ALPHAMINR

PHAT 10-Q Quarter ended Sept. 30, 2022

Balance Sheet
Cash Flow
Income Statement
Debt
CIK: 1783183
Filing Type: 10-Q/A
Report Date: 2022-09-30
Download URL: https://www.sec.gov/Archives/edgar/data/1783183/000095017022023372/phat-20220930.htm
]]>
TABLE OF CONTENTS
Part I. FinanciItem 1. Financial Statements (unaudited)Item 1. Financial StItem 2. Management S Discussion and Analysis Of Financial Condition and Results Of OperationsItem 2. Management S Discussion and Analysis OItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 3. Quantitative and QualitatItem 4. Controls and ProceduresItem 4. ControlsPart II. Other InformationPart II. OtherItem 1. Legal ProceedingsItem 1. LegalItem 1A. Risk FactorsItem 1A. RiItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsItem 2. Unregistered Sales Of EquiItem 3. Defaults Upon Senior SecuritiesItem 3. Defaults UpoItem 4. Mine Safety DisclosuresItem 4. Mine SafItem 5. Other InformationItem 5. OtherItem 6. Exhibits

Exhibits

3.1 Amended and Restated Certificate of Incorporation 8-K 10/29/19 3.1 3.2 Amended and Restated Bylaws 8-K 09/25/2020 3.1 4.1 Form of Common Stock Certificate S-1/A 10/15/19 4.1 4.2 Warrant to purchase shares of common stock issued to Takeda Company Limited, dated May 7, 2019 S-1 9/30/19 4.2 4.3 Warrant to purchase stock issued to Silicon Valley Bank, dated May 14, 2019 S-1 9/30/19 4.3 4.4 Warrant to purchase stock issued to WestRiver Innovation Lending Fund VIII, L.P., dated May 14, 2019 S-1 9/30/19 4.4 4.5 Note Purchase Agreement, dated May 7, 2019, by and among the Registrant and the other parties party thereto, as amended S-1/A 10/15/19 4.5 4.6 Description of Registered Securities 10-K 12/31/21 4.6 10.1 Commercial Supply Agreement with Evonik Operations GmbH entered into on August 1, 2022 10.2 Second Amendment to the Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant. 31.1 Certification of Chief Executive Officer of Phathom Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Chief Financial Officer of Phathom Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1* Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2* Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.